SBA loans for pharmacies

Pharmacy lending leans toward acquisitions

Pharmacies and drug retailers (NAICS 456110) took 708 SBA 7(a) loans from FY2024 through June 2026, worth $495,022,400, from 141 lenders. They borrowed large: the median loan of $356,050 is more than twice the national median, the middle half ran from $150,000 to $918,000, and the top tenth started at $1,896,500.

The share that sets pharmacy apart is acquisitions. 130 loans, 18.4% of the total, financed a change of ownership, well above the national 10.4%, at a median of $1,245,000 and a median rate of 9.5%. Independent pharmacies change hands between pharmacists, and SBA is how many of those sales are paid for. Start-ups were another 17.1%.

The median loan sits just above $350,000, which is where SBA's tightest rate cap begins: base rate plus 3% for loans above $350,000. About half of pharmacy loans fall under that cap, which helps explain a median rate below the national one. See SBA loan rates.

What a lender reads in a pharmacy

A pharmacy can post large sales and thin profits. Most of its revenue is prescriptions, and most prescriptions are paid by insurers through pharmacy benefit managers, which set the reimbursement. So lenders look past sales to the figures that show what the pharmacy keeps:

Two further questions come up in almost every pharmacy file. The first is audits: payers audit pharmacy claims and can recover payments they find unsupported, so lenders ask for the audit history and any open findings. The second is concentration. A pharmacy serving a nursing home, a clinic's patients or a single employer's plan has a customer that can leave, and the lender will ask how much of the prescription volume depends on it.

Inventory: collateral, and part of the price

Drug inventory is the one substantial tangible asset most pharmacies own. In a purchase it is commonly counted at closing and paid for at cost on top of the price for the business, which is why a pharmacy acquisition needs more cash than the goodwill figure alone suggests. The lender finances it as part of the project, and the buyer should also keep enough working capital to restock and to carry the gap between filling a prescription and being paid for it. See working capital at close.

As collateral, inventory is worth less to a lender than to the pharmacy. Where lenders advance against inventory, it typically advances at up to 85% of net orderly liquidation value, or roughly half of cost, and controlled substances and short-dated stock are harder to liquidate than their book value suggests. See inventory advance rates.

Licenses and payer contracts do not come with the keys

What makes a pharmacy purchase different from buying most retailers is that its right to operate and to be paid is held in registrations and contracts, and many of them do not simply transfer to a new owner. Depending on the state and the structure of the deal, a buyer may need its own state pharmacy permit, DEA registration for controlled substances, provider identifiers, Medicare and Medicaid enrollment, and new or assigned contracts with the benefit managers whose networks the pharmacy fills for.

• Timing. Until the new owner is credentialed with the payers, it may not be able to bill for most prescriptions. Lenders set closing conditions around the licenses and contracts and want a plan for the transition.
• Stock or asset purchase. Buying the entity can keep some registrations in place where an asset purchase would require new ones, but it also brings the entity's audit history and liabilities with it. See asset vs stock purchase financing.
• The pharmacist in charge. A buyer who is not a pharmacist needs one, and the lender will want to know who it is and whether they are committed. Where the seller is the pharmacist the patients know, SBA lets the seller consult for up to 12 months after closing, up to 24 months under SOP 50 10 8.1 from 1 October 2026, but not remain an owner, officer or employee.

In a pharmacy purchase, the lender underwrites the buyer's ability to keep billing on day one as closely as it underwrites the store's earnings.

Buying a pharmacy under SBA's rules

The median purchase loan of $1,245,000 is mostly goodwill and inventory, so SBA's valuation rule applies to nearly every deal: where the amount financed, less appraised real estate and equipment, exceeds $250,000, SBA requires an independent business valuation, and the loan for the purchase cannot exceed it. The buyer brings an equity injection of at least 10% of total project costs; a seller note can count for up to half of it, but only if it is on full standby for the life of the loan, and SBA prohibits an earnout. See SBA's business valuation requirement and seller notes and SBA standby.

Loans numbered from 1 October 2026 add financial due diligence on every change of ownership, a quality of earnings report on acquisitions of $3 million or more excluding real estate, and coverage of 1.25x on historical results. The median pharmacy purchase is below the quality of earnings line, but a buyer taking on two or three stores can cross it. Where the store's building is in the deal, the real estate share can run up to 25 years while the rest runs up to 10. See acquisitions with real estate and financing a pharmacy acquisition.

Opening a new pharmacy

Start-ups were 17.1% of loans. A new independent has no prescription history, so lenders underwrite the pharmacist: years in practice, management experience, and whether patients or prescribers are likely to follow. They also look at the location and its competition, the plan for payer contracts, and how long the projection assumes it takes for volume to cover costs. SBA requires an equity injection of at least 10% of total project costs, and a lender will want the opening inventory and working capital funded, not squeezed.

Preparing a pharmacy's file

SBA's standard documents: business tax returns for 2–3 years, a P&L and balance sheet with a year-to-date P&L through last month-end, a debt schedule with copies of notes being refinanced, and personal tax returns and a personal financial statement for each owner of 20% or more. The pharmacist's resume supports Form 1919.

For a pharmacy, add prescription counts and gross profit per prescription by month, payer mix, an inventory report, the list of licenses and payer contracts with their holders, and any audit correspondence. For a purchase, add the target's latest full year of figures, never an older year, and the letter of intent.

Transparent builds that into a full lender package — financing model, lender presentation, blind teaser and underwriting memo — in a day once the documents are in, and sends it to the lenders in its book that fit: 278 write SBA 7(a) and 504, and 235 write asset-based loans and lines for an inventory-backed facility. On SBA loans the lender pays Transparent, not the borrower. See the package.